NDAORALSOLUTION
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
ELYXYB (celecoxib) by Inpharmus is cyclooxygenase inhibitors [moa]. Approved for osteoarthritis, pain. First approved in 2020.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ELYXYB is an oral celecoxib solution approved in 2020 for pain management and inflammatory conditions including osteoarthritis, acute post-surgical pain, and ankylosing spondylitis. It is a selective cyclooxygenase (COX) inhibitor that reduces inflammation and pain. The solution formulation differentiates it from tablet-based celecoxib competitors.
$0.604MPart D
Peak10.1 years to LOEProduct is in peak lifecycle phase but with minimal Part D penetration ($604K annually, 531 claims in 2023), suggesting limited commercial scale and potential for modest team resources.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications (2)
Clinical Trials (20)
Bioequivalence Study of Generic Celecoxib 200 mg Capsules
Started Sep 2024
40 enrolled
Healthy Volunteer
Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers
Started Jun 2022
59 enrolled
Healthy Volunteers
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
Started Jun 2022
25 enrolled
Colorectal Cancer
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
Started Jan 2019
53 enrolled
Malignant Pleural Mesothelioma
Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.
Started Mar 2017
637 enrolled
Acute Post-surgical Pain
Worked on ELYXYB at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.